NasdaqCM:CAPRBiotechs
A Look At Capricor Therapeutics (CAPR) Valuation As FDA Advances Review Of Deramiocel BLA
Regulatory update and why it matters for Capricor investors
Capricor Therapeutics (CAPR) shares are in focus after the company reported a new step in the U.S. regulatory process for Deramiocel, its investigational cell therapy for Duchenne muscular dystrophy.
The FDA has requested the full Phase 3 HOPE-3 clinical study report and supporting data to address a prior Complete Response Letter, without asking for new clinical trials or additional patient data.
See our latest analysis for Capricor...